Biogen's $5.6 Billion Acquisition of Apellis to Strengthen Kidney Disease Portfolio

Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion in cash, paying $41 per share plus contingent value rights. This acquisition aims to enhance Biogen's growth portfolio in immunology and rare diseases, particularly boosting its kidney disease franchise. The deal has caused Apellis shares to surge over 100% in premarket trading, reflecting market optimism about Biogen's strategic expansion into nephrology.

Latest News

04-01

the Biotech Growth Trust Plc: Biogen, Inc. to Acquire Biog Portfolio Company, Apellis Pharmaceuticals, Inc.

04-01

Post-Bell｜Nasdaq Soars 3.8% as Traders Bet on Potential War Off-Ramp. Nvidia, Micron Jump Around 5%; Meta Gains over 6%; Marvell Soars 13%

04-01

Biogen - Enters Merger Agreement With Apellis Pharmaceuticals on March 31, 2026 - SEC Filing

User Discussion

CC on ETFs

04-02

Biotech Surges Against the Trend, XBI Jumps 7.5%—Why?

On March 31, the US and Iran signaled a potential de-escalation of conflict, leading to a clear improvement in market risk appetite. US equities broadly rallied, with the $NASDAQ(.IXIC)$ rising 3.80% on the day. Against this backdrop, the biotech sector stood out, with $Spdr S&P Biotech Etf(XBI)$ gaining 7.53%, significantly outperforming the broader market. Looking over a longer time frame, this performance did not emerge in a single day. As of the March 31 close, XBI has risen approximately 4.8% compared to December 31, 2025, while the Nasdaq has declined about 7.1% over the same period. Since the escalation of tensions in the Middle East on February 28, volatility in tech stocks has increased, whil

Biotech Surges Against the Trend, XBI Jumps 7.5%—Why?

{"i18n":{"language":"en_US"},"financialEventData":{"themeId":"b2495f52240e7e9378faffff6c56a404","name":"Biogen's $5.6 Billion Acquisition of Apellis to Strengthen Kidney Disease Portfolio","description":"Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion in cash, paying $41 per share plus contingent value rights. This acquisition aims to enhance Biogen's growth portfolio in immunology and rare diseases, particularly boosting its kidney disease franchise. The deal has caused Apellis shares to surge over 100% in premarket trading, reflecting market optimism about Biogen's strategic expansion into nephrology.","image":"https://community-static.tradeup.com/news/1201dcc0482be040348fb8d4f228bb68","type":2,"style":4,"follow":false,"createTime":1774955717924,"userCounts":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/special/finance&rndata={\"themeId\":b2495f52240e7e9378faffff6c56a404}&rnconfig={\"headerBarHidden\": true}","subscribe":false,"allowSubscriptionFinancial":false,"subscriberCount":0,"allowFollow":false,"hasReward":false,"rewardScore":0,"rewardValidDate":0,"rewardEnd":false,"symbols":["BIIB","APLS"],"tweetCounts":1,"categoryId":"2929bb7468f5415f853fd96fb35d7c3b","options":[],"votedOptionId":"","totalUserCount":0,"followStatus":false,"themeName":"Biogen's $5.6 Billion Acquisition of Apellis to Strengthen Kidney Disease Portfolio","tweetAmount":1,"imageIsDefault":false,"aiDerivativeIssues":[]},"news":[{"id":549354,"article_id":"2624641285","title":"the Biotech Growth Trust Plc: Biogen, Inc. to Acquire Biog Portfolio Company, Apellis Pharmaceuticals, Inc.","subtitle":"","subtitle_show":0,"pub_time":1775023231866,"source_id":"reuters_en_live","language":"en","url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nTUA25J48H:1","is_publish_highlight":0,"top_time":0,"symbols_score_info":{},"rights":null},{"id":548697,"article_id":"1132258309","title":"Post-Bell｜Nasdaq Soars 3.8% as Traders Bet on Potential War Off-Ramp. Nvidia, Micron Jump Around 5%; Meta Gains over 6%; Marvell Soars 13%","subtitle":"","subtitle_show":0,"pub_time":1775002027000,"source_id":"","language":"en","url":"","is_publish_highlight":1,"top_time":0,"symbols_score_info":{".DJI":1,".IXIC":1,".SPX":1},"rights":null},{"id":548574,"article_id":"2624538955","title":"Biogen - Enters Merger Agreement With Apellis Pharmaceuticals on March 31, 2026 - SEC Filing","subtitle":"","subtitle_show":0,"pub_time":1774991132330,"source_id":"reuters_en_live","language":"en","url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J1OO:1","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"BIIB":0.9},"rights":null},{"id":548487,"article_id":"2624530323","title":"U.S. Small Caps Rise; Apellis Pharmaceuticals Leads Increases","subtitle":"","subtitle_show":0,"pub_time":1774988460000,"source_id":"dowjones_highlight","language":"en","url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":0,"top_time":0,"symbols_score_info":{},"rights":null},{"id":548098,"article_id":"2623158094","title":"Biogen Lands Two Fast-Growing Drugs In Blockbuster Apellis Deal","subtitle":"","subtitle_show":0,"pub_time":1774966560000,"source_id":"benzinga_hot_news","language":"en","url":"https://www.benzinga.com/m-a/26/03/51569831/biogen-lands-two-fast-growing-drugs-in-blockbuster-apellis-deal","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"BIIB":1.5,"CVR":1},"rights":null},{"id":547851,"article_id":"1149102155","title":"渤健公司同意以56亿美元收购Apellis Pharmaceuticals，股价跌至1月以来最低点，日内跌幅达7.7%","subtitle":"","subtitle_show":0,"pub_time":1774963995564,"source_id":"美股速递","language":"zh","url":"","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"APLS":1,"BIIB":1},"rights":null},{"id":547852,"article_id":"2623582490","title":"Biogen Shares Hit Lowest Since January, Last Down 7.7% After Agreeing to $5.6 Bln Buyout of Apellis Pharmaceuticals","subtitle":"","subtitle_show":0,"pub_time":1774963954491,"source_id":"reuters_en_live","language":"en","url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J1MK:1","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"APLS":0.9,"BIIB":0.9},"rights":null},{"id":547785,"article_id":"2623584765","title":"溢价一倍收购Apellis(APLS.US) 百健(BIIB.US)56亿美元重注免疫学与罕见病赛道","subtitle":"","subtitle_show":0,"pub_time":1774962488000,"source_id":"live_zhitongcaijing","language":"zh","url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":0,"top_time":0,"symbols_score_info":{},"rights":null},{"id":547756,"article_id":"2623458431","title":"渤健将斥资56亿美元收购制药公司Apellis","subtitle":"","subtitle_show":0,"pub_time":1774961763000,"source_id":"live_gelonghui","language":"zh","url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"01477":1.5},"rights":null},{"id":547736,"article_id":"1120207333","title":"Pre-Bell | M&A Flurry Lifts Apellis 138% as Biogen, Lilly, Unilever and Allbirds Deals Stir U.S. Pre-Market; Futures Advance While Dollar and Yields Ease","subtitle":"","subtitle_show":0,"pub_time":1774960200000,"source_id":"","language":"en","url":"","is_publish_highlight":1,"top_time":0,"symbols_score_info":{"ESmain":1,"NQmain":1,"YMmain":1},"rights":null},{"id":547732,"article_id":"2623858686","title":"Apellis(APLS)盘前涨超142% Biogen(BIIB)将以56亿美元收购该公司","subtitle":"","subtitle_show":0,"pub_time":1774956713000,"source_id":"jinwu_rss","language":"zh","url":"298590","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"APLS":1.5,"BIIB":1.5,"BLLB":0.9},"rights":null},{"id":547731,"article_id":"1141061041","title":"美股盘前｜Apellis涨超138%，CNTA涨超47%，迈威尔科技涨超11%；特朗普称各国应自行去霍尔木兹海峡“抢石油”","subtitle":"","subtitle_show":0,"pub_time":1774956695030,"source_id":"","language":"zh","url":"","is_publish_highlight":1,"top_time":0,"symbols_score_info":{".DJI":2,".IXIC":2,".SPX":2,"NVDA":2,"TSLA":2},"rights":null},{"id":547734,"article_id":"2623858245","title":"百健公司斥资 56 亿美元收购 Apellis，推动罕见病领域发展","subtitle":"","subtitle_show":0,"pub_time":1774956010000,"source_id":"reuters_news_zh","language":"zh","url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nL4T40J10A:1","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"APLS":0.9,"BIIB":0.9},"rights":null},{"id":547452,"article_id":"1194919912","title":"异动解读 | 渤健56亿美元收购消息推动，Apellis制药盘前暴涨140.96%","subtitle":"","subtitle_show":0,"pub_time":1774955856428,"source_id":"ai_movement_cn","language":"zh","url":"","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"APLS":1},"rights":null},{"id":547453,"article_id":"1136040864","title":"Stock Track | Apellis Pharmaceuticals Soars 140.96% in Pre-Market on $5.6 Billion Biogen Acquisition","subtitle":"","subtitle_show":0,"pub_time":1774955807573,"source_id":"ai_movement_en","language":"en","url":"","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"APLS":1},"rights":null},{"id":547733,"article_id":"2623246583","title":"Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion in Cash Plus Contingency Payments","subtitle":"","subtitle_show":0,"pub_time":1774955613000,"source_id":"mtnewswires_news","language":"en","url":"https://www.mtnewswires.com/","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"APLS":0.9,"BIIB":1.5},"rights":null},{"id":547391,"article_id":"2623583232","title":"美股异动 | Apellis盘前暴涨140% Biogen将以56亿美元收购该公司","subtitle":"","subtitle_show":0,"pub_time":1774955583000,"source_id":"live_gelonghui","language":"zh","url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":0,"top_time":0,"symbols_score_info":{},"rights":null},{"id":547405,"article_id":"2623758364","title":"百健公司将以 56 亿美元收购 Apellis 制药公司","subtitle":"","subtitle_show":0,"pub_time":1774954981000,"source_id":"reuters_news_zh","language":"zh","url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nL4S40J0Y3:1","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"APLS":0.9,"BIIB":0.9},"rights":null},{"id":547398,"article_id":"1167344429","title":"Biogen to Buy Apellis for $5.6 Billion to Boost Kidney Franchise","subtitle":"","subtitle_show":0,"pub_time":1774954829976,"source_id":"","language":"en","url":"","is_publish_highlight":1,"top_time":0,"symbols_score_info":{"APLS":2,"BIIB":2},"rights":null},{"id":547402,"article_id":"2623583543","title":"Biogen to acquire Apellis for $41.00 per share in cash at closing, or $5.6B","subtitle":"","subtitle_show":0,"pub_time":1774954821000,"source_id":"tipranks_highlight","language":"en","url":"https://www.tipranks.com/news/the-fly/biogen-to-acquire-apellis-for-41-00-per-share-in-cash-at-closing-or-5-6b-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"APLS":1,"BIIB":1.5},"rights":null},{"id":547390,"article_id":"1129135901","title":"渤健公司收购Apellis制药，强化免疫学与罕见病产品组合，提升增长前景并加速肾病领域扩张","subtitle":"","subtitle_show":0,"pub_time":1774954764098,"source_id":"美股速递","language":"zh","url":"","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"APLS":1,"BIIB":1},"rights":null},{"id":547393,"article_id":"2623583831","title":"Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion Into Nephrology","subtitle":"","subtitle_show":0,"pub_time":1774954740483,"source_id":"reuters_en_live","language":"en","url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUA690DZF:1","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"APLS":0.9,"BIIB":0.9},"rights":null},{"id":547394,"article_id":"2623583824","title":"Biogen - Biogen to Acquire Apellis for a Price of $41 per Share in Cash","subtitle":"","subtitle_show":0,"pub_time":1774954740464,"source_id":"reuters_en_live","language":"en","url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUAWGYMW:3","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"APLS":0.9,"BIIB":0.9},"rights":null},{"id":547730,"article_id":"2623585580","title":"Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology","subtitle":"","subtitle_show":0,"pub_time":1774954740000,"source_id":"intrado","language":"en","url":"https://www.globenewswire.com/news-release/2026/03/31/3265288/0/en/Biogen-to-Acquire-Apellis-Enhancing-the-Company-s-Growth-Portfolio-in-Immunology-and-Rare-Disease-Bolstering-Growth-Outlook-and-Accelerating-Expansion-into-Nephrology.html","is_publish_highlight":0,"top_time":0,"symbols_score_info":{},"rights":null},{"id":547729,"article_id":"2623585586","title":"Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology","subtitle":"","subtitle_show":0,"pub_time":1774954740000,"source_id":"intrado","language":"en","url":"https://www.globenewswire.com/news-release/2026/03/31/3265287/0/en/Biogen-to-Acquire-Apellis-Enhancing-the-Company-s-Growth-Portfolio-in-Immunology-and-Rare-Disease-Bolstering-Growth-Outlook-and-Accelerating-Expansion-into-Nephrology.html","is_publish_highlight":0,"top_time":0,"symbols_score_info":{},"rights":null},{"id":547404,"article_id":"1199461216","title":"传渤健56亿美元收购Apellis强化肾病业务，后者股价盘前暴涨逾一倍","subtitle":"","subtitle_show":0,"pub_time":1774954530714,"source_id":"美股速递","language":"zh","url":"","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"APLS":1,"BIIB":1},"rights":null},{"id":547388,"article_id":"1166661258","title":"Biogen将以每股41美元现金加CVR（或有价值权）收购Apellis制药","subtitle":"","subtitle_show":0,"pub_time":1774954525196,"source_id":"","language":"zh","url":"","is_publish_highlight":1,"top_time":0,"symbols_score_info":{"APLS":2,"BIIB":2},"rights":null},{"id":547401,"article_id":"2623880665","title":"Apellis Shares More Than Double in Value in Premarket Trading After Report Biogen to Buy Co for $5.6 Bln to Boost Kidney Franchise","subtitle":"","subtitle_show":0,"pub_time":1774954477000,"source_id":"reuters_en_live","language":"en","url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nL4N40J0XG:1","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"APLS":0.9,"BIIB":0.9},"rights":null},{"id":547397,"article_id":"2623588082","title":"BRIEF-Biogen To Buy Apellis For $5.6 Billion To Boost Kidney Franchise - Bloomberg News","subtitle":"","subtitle_show":0,"pub_time":1774954437000,"source_id":"reuters_news_en","language":"en","url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J0Y4:1","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"APLS":0.9,"BIIB":0.9},"rights":null},{"id":547399,"article_id":"2623588774","title":"Biogen to Buy Apellis for $5.6 Billion to Boost Kidney Franchise - Bloomberg News","subtitle":"","subtitle_show":0,"pub_time":1774954298891,"source_id":"reuters_en_live","language":"en","url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J0Y4:1","is_publish_highlight":0,"top_time":0,"symbols_score_info":{"APLS":0.9,"BIIB":0.9},"rights":null}],"views":[],"tweetList":[{"id":549236372677800,"gmtCreate":1775114777855,"gmtModify":1775135967615,"author":{"id":"4230875998456352","authorId":"4230875998456352","name":"CC on ETFs","avatar":"https://community-static.tradeup.com/news/06924e783aa8067af00f2aa1262f381c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4230875998456352","authorIdStr":"4230875998456352"},"themes":[],"title":"Biotech Surges Against the Trend, XBI Jumps 7.5%—Why?","htmlText":"On March 31, the US and Iran signaled a potential de-escalation of conflict, leading to a clear improvement in market risk appetite. US equities broadly rallied, with the <a href=\"https://ttm.financial/S/.IXIC\">$NASDAQ(.IXIC)$</a> rising 3.80% on the day. Against this backdrop, the biotech sector stood out, with <a href=\"https://ttm.financial/S/XBI\">$Spdr S&amp;P Biotech Etf(XBI)$</a> gaining 7.53%, significantly outperforming the broader market. Looking over a longer time frame, this performance did not emerge in a single day. As of the March 31 close, XBI has risen approximately 4.8% compared to December 31, 2025, while the Nasdaq has declined about 7.1% over the same period. Since the escalation of tensions in the Middle East on February 28, volatility in tech stocks has increased, whil","listText":"On March 31, the US and Iran signaled a potential de-escalation of conflict, leading to a clear improvement in market risk appetite. US equities broadly rallied, with the <a href=\"https://ttm.financial/S/.IXIC\">$NASDAQ(.IXIC)$</a> rising 3.80% on the day. Against this backdrop, the biotech sector stood out, with <a href=\"https://ttm.financial/S/XBI\">$Spdr S&amp;P Biotech Etf(XBI)$</a> gaining 7.53%, significantly outperforming the broader market. Looking over a longer time frame, this performance did not emerge in a single day. As of the March 31 close, XBI has risen approximately 4.8% compared to December 31, 2025, while the Nasdaq has declined about 7.1% over the same period. Since the escalation of tensions in the Middle East on February 28, volatility in tech stocks has increased, whil","text":"On March 31, the US and Iran signaled a potential de-escalation of conflict, leading to a clear improvement in market risk appetite. US equities broadly rallied, with the $NASDAQ(.IXIC)$ rising 3.80% on the day. Against this backdrop, the biotech sector stood out, with $Spdr S&P Biotech Etf(XBI)$ gaining 7.53%, significantly outperforming the broader market. Looking over a longer time frame, this performance did not emerge in a single day. As of the March 31 close, XBI has risen approximately 4.8% compared to December 31, 2025, while the Nasdaq has declined about 7.1% over the same period. Since the escalation of tensions in the Middle East on February 28, volatility in tech stocks has increased, whil","images":[{"img":"https://community-static.tradeup.com/news/e66a884917504de5529f69a2b61f1c3b"},{"img":"https://community-static.tradeup.com/news/0b9a8ed7f59f8d2c304eb65d83fa5f56"},{"img":"https://community-static.tradeup.com/news/e86a82f80abf4011139222f26f50cfd2"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":210,"commentSize":1,"repostSize":16,"link":"https://ttm.financial/post/549236372677800","isVote":1,"tweetType":1,"viewCount":2666,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000690","authorId":"9000000000000690","name":"BelindaHaywood","avatar":"https://static.tigerbbs.com/4978f4a510bcf43d5d844a52ae86fd92","crmLevel":1,"crmLevelSwitch":0,"idStr":"9000000000000690","authorIdStr":"9000000000000690"},"content":"Biotech's smashing it! XBI's run is solid. [666]","text":"Biotech's smashing it! XBI's run is solid. [666]","html":"Biotech's smashing it! XBI's run is solid. [666]"}],"imageCount":3,"langContent":"EN","totalScore":0}]}